nodes	percent_of_prediction	percent_of_DWPC	metapath
Drospirenone—AR—scrotum—sarcoma	0.0927	0.145	CbGeAlD
Drospirenone—BCHE—diaphragm—sarcoma	0.0626	0.0978	CbGeAlD
Drospirenone—PTGS2—periosteum—sarcoma	0.0278	0.0435	CbGeAlD
Drospirenone—PTGS2—leg—sarcoma	0.0222	0.0346	CbGeAlD
Drospirenone—PTGS2—hindlimb—sarcoma	0.0198	0.0309	CbGeAlD
Drospirenone—PTGS2—cartilage tissue—sarcoma	0.0195	0.0304	CbGeAlD
Drospirenone—PTGS2—appendage—sarcoma	0.017	0.0265	CbGeAlD
Drospirenone—PGR—mammary gland—sarcoma	0.0165	0.0259	CbGeAlD
Drospirenone—Cerebral infarction—Vincristine—sarcoma	0.0155	0.0929	CcSEcCtD
Drospirenone—PGR—Ovarian Infertility Genes—GJA4—sarcoma	0.0137	0.0709	CbGpPWpGaD
Drospirenone—NR3C2—myometrium—sarcoma	0.0126	0.0197	CbGeAlD
Drospirenone—PGR—myometrium—sarcoma	0.0117	0.0183	CbGeAlD
Drospirenone—NR3C2—seminal vesicle—sarcoma	0.0114	0.0178	CbGeAlD
Drospirenone—NR3C2—hematopoietic system—sarcoma	0.0108	0.0169	CbGeAlD
Drospirenone—NR3C2—connective tissue—sarcoma	0.0104	0.0163	CbGeAlD
Drospirenone—PTGS2—endothelium—sarcoma	0.0103	0.016	CbGeAlD
Drospirenone—PGR—hematopoietic system—sarcoma	0.0101	0.0158	CbGeAlD
Drospirenone—PGR—connective tissue—sarcoma	0.00971	0.0152	CbGeAlD
Drospirenone—NR3C2—smooth muscle tissue—sarcoma	0.00955	0.0149	CbGeAlD
Drospirenone—AR—myometrium—sarcoma	0.00935	0.0146	CbGeAlD
Drospirenone—PGR—smooth muscle tissue—sarcoma	0.00888	0.0139	CbGeAlD
Drospirenone—Embolism—Thiotepa—sarcoma	0.00887	0.0532	CcSEcCtD
Drospirenone—AR—seminal vesicle—sarcoma	0.00845	0.0132	CbGeAlD
Drospirenone—NR3C2—cardiac atrium—sarcoma	0.00823	0.0129	CbGeAlD
Drospirenone—NR3C2—uterus—sarcoma	0.00819	0.0128	CbGeAlD
Drospirenone—AR—hematopoietic system—sarcoma	0.00803	0.0125	CbGeAlD
Drospirenone—Venous thromboembolism—Epirubicin—sarcoma	0.0078	0.0468	CcSEcCtD
Drospirenone—AR—connective tissue—sarcoma	0.00773	0.0121	CbGeAlD
Drospirenone—PGR—uterus—sarcoma	0.00761	0.0119	CbGeAlD
Drospirenone—BCHE—myometrium—sarcoma	0.00761	0.0119	CbGeAlD
Drospirenone—Venous thromboembolism—Doxorubicin—sarcoma	0.00721	0.0433	CcSEcCtD
Drospirenone—NR3C2—tendon—sarcoma	0.00718	0.0112	CbGeAlD
Drospirenone—PGR—lymphoid tissue—sarcoma	0.0071	0.0111	CbGeAlD
Drospirenone—AR—smooth muscle tissue—sarcoma	0.00707	0.0111	CbGeAlD
Drospirenone—AR—FOXA1 transcription factor network—COL18A1—sarcoma	0.00698	0.0361	CbGpPWpGaD
Drospirenone—AR—skin of body—sarcoma	0.00698	0.0109	CbGeAlD
Drospirenone—BCHE—seminal vesicle—sarcoma	0.00688	0.0107	CbGeAlD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—COL18A1—sarcoma	0.00679	0.0351	CbGpPWpGaD
Drospirenone—BCHE—hematopoietic system—sarcoma	0.00653	0.0102	CbGeAlD
Drospirenone—AR—cardiac atrium—sarcoma	0.0061	0.00953	CbGeAlD
Drospirenone—AR—uterus—sarcoma	0.00607	0.00948	CbGeAlD
Drospirenone—AR—Notch-mediated HES/HEY network—TLE1—sarcoma	0.00595	0.0308	CbGpPWpGaD
Drospirenone—NR3C2—testis—sarcoma	0.00594	0.00929	CbGeAlD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—sarcoma	0.0059	0.0305	CbGpPWpGaD
Drospirenone—PTGS2—myometrium—sarcoma	0.00586	0.00916	CbGeAlD
Drospirenone—BCHE—smooth muscle tissue—sarcoma	0.00576	0.00899	CbGeAlD
Drospirenone—BCHE—skin of body—sarcoma	0.00568	0.00888	CbGeAlD
Drospirenone—AR—lymphoid tissue—sarcoma	0.00565	0.00883	CbGeAlD
Drospirenone—PTGS2—embryo—sarcoma	0.00564	0.00881	CbGeAlD
Drospirenone—NR3C2—liver—sarcoma	0.00562	0.00878	CbGeAlD
Drospirenone—AR—Notch-mediated HES/HEY network—MYOD1—sarcoma	0.00558	0.0289	CbGpPWpGaD
Drospirenone—PGR—testis—sarcoma	0.00552	0.00863	CbGeAlD
Drospirenone—AR—Nongenotropic Androgen signaling—PLCG1—sarcoma	0.0055	0.0285	CbGpPWpGaD
Drospirenone—AR—tendon—sarcoma	0.00532	0.00831	CbGeAlD
Drospirenone—PTGS2—seminal vesicle—sarcoma	0.0053	0.00828	CbGeAlD
Drospirenone—PTGS2—hematopoietic system—sarcoma	0.00503	0.00787	CbGeAlD
Drospirenone—BCHE—cardiac atrium—sarcoma	0.00496	0.00775	CbGeAlD
Drospirenone—BCHE—uterus—sarcoma	0.00494	0.00771	CbGeAlD
Drospirenone—PTGS2—connective tissue—sarcoma	0.00485	0.00757	CbGeAlD
Drospirenone—PTGS2—S1P1 pathway—PLCG1—sarcoma	0.00468	0.0242	CbGpPWpGaD
Drospirenone—Embolism venous—Epirubicin—sarcoma	0.00454	0.0272	CcSEcCtD
Drospirenone—PTGS2—smooth muscle tissue—sarcoma	0.00443	0.00693	CbGeAlD
Drospirenone—AR—testis—sarcoma	0.0044	0.00688	CbGeAlD
Drospirenone—PTGS2—skin of body—sarcoma	0.00438	0.00684	CbGeAlD
Drospirenone—NR3C2—lymph node—sarcoma	0.00431	0.00673	CbGeAlD
Drospirenone—Embolism venous—Doxorubicin—sarcoma	0.0042	0.0252	CcSEcCtD
Drospirenone—BCHE—bone marrow—sarcoma	0.00419	0.00655	CbGeAlD
Drospirenone—AR—liver—sarcoma	0.00416	0.0065	CbGeAlD
Drospirenone—PGR—lymph node—sarcoma	0.004	0.00626	CbGeAlD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TLE1—sarcoma	0.00389	0.0201	CbGpPWpGaD
Drospirenone—PTGS2—uterus—sarcoma	0.0038	0.00594	CbGeAlD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.00377	0.0195	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.00361	0.0187	CbGpPWpGaD
Drospirenone—BCHE—testis—sarcoma	0.00358	0.00559	CbGeAlD
Drospirenone—Embolism—Epirubicin—sarcoma	0.00357	0.0214	CcSEcCtD
Drospirenone—PTGS2—lymphoid tissue—sarcoma	0.00354	0.00554	CbGeAlD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—sarcoma	0.00339	0.0175	CbGpPWpGaD
Drospirenone—BCHE—liver—sarcoma	0.00339	0.00529	CbGeAlD
Drospirenone—PTGS2—tendon—sarcoma	0.00333	0.00521	CbGeAlD
Drospirenone—PTGS2—S1P1 pathway—PDGFRB—sarcoma	0.00332	0.0172	CbGpPWpGaD
Drospirenone—Embolism—Doxorubicin—sarcoma	0.0033	0.0198	CcSEcCtD
Drospirenone—Thrombosis—Epirubicin—sarcoma	0.00324	0.0194	CcSEcCtD
Drospirenone—PTGS2—bone marrow—sarcoma	0.00323	0.00504	CbGeAlD
Drospirenone—AR—lymph node—sarcoma	0.00319	0.00498	CbGeAlD
Drospirenone—Thrombosis—Doxorubicin—sarcoma	0.003	0.018	CcSEcCtD
Drospirenone—Haemoglobin—Thiotepa—sarcoma	0.00287	0.0172	CcSEcCtD
Drospirenone—Haemorrhage—Thiotepa—sarcoma	0.00286	0.0171	CcSEcCtD
Drospirenone—AR—Nongenotropic Androgen signaling—CREB1—sarcoma	0.00283	0.0147	CbGpPWpGaD
Drospirenone—Depression—Vincristine—sarcoma	0.00282	0.0169	CcSEcCtD
Drospirenone—Acute coronary syndrome—Vincristine—sarcoma	0.00278	0.0167	CcSEcCtD
Drospirenone—Myocardial infarction—Vincristine—sarcoma	0.00277	0.0166	CcSEcCtD
Drospirenone—PTGS2—S1P1 pathway—KDR—sarcoma	0.00275	0.0142	CbGpPWpGaD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.00273	0.0141	CbGpPWpGaD
Drospirenone—Acute coronary syndrome—Mitoxantrone—sarcoma	0.00271	0.0163	CcSEcCtD
Drospirenone—Myocardial infarction—Mitoxantrone—sarcoma	0.0027	0.0162	CcSEcCtD
Drospirenone—Erythema multiforme—Dactinomycin—sarcoma	0.00268	0.0161	CcSEcCtD
Drospirenone—Breast pain—Epirubicin—sarcoma	0.00263	0.0158	CcSEcCtD
Drospirenone—PTGS2—liver—sarcoma	0.00261	0.00408	CbGeAlD
Drospirenone—BCHE—lymph node—sarcoma	0.0026	0.00406	CbGeAlD
Drospirenone—Angiopathy—Thiotepa—sarcoma	0.00259	0.0156	CcSEcCtD
Drospirenone—AR—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.00254	0.0132	CbGpPWpGaD
Drospirenone—Mental disorder—Thiotepa—sarcoma	0.0025	0.015	CcSEcCtD
Drospirenone—Haemoglobin—Mitoxantrone—sarcoma	0.00248	0.0149	CcSEcCtD
Drospirenone—Haemorrhage—Mitoxantrone—sarcoma	0.00247	0.0148	CcSEcCtD
Drospirenone—Breast pain—Doxorubicin—sarcoma	0.00243	0.0146	CcSEcCtD
Drospirenone—AR—Notch-mediated HES/HEY network—KDR—sarcoma	0.00232	0.012	CbGpPWpGaD
Drospirenone—Angiopathy—Vincristine—sarcoma	0.0023	0.0138	CcSEcCtD
Drospirenone—Acute coronary syndrome—Etoposide—sarcoma	0.00225	0.0135	CcSEcCtD
Drospirenone—Myocardial infarction—Etoposide—sarcoma	0.00224	0.0134	CcSEcCtD
Drospirenone—Mental disorder—Vincristine—sarcoma	0.00222	0.0133	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.0021	0.0126	CcSEcCtD
Drospirenone—PTGS2—C-MYB transcription factor network—MYOD1—sarcoma	0.00202	0.0104	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—CD34—sarcoma	0.00202	0.0104	CbGpPWpGaD
Drospirenone—PTGS2—lymph node—sarcoma	0.002	0.00312	CbGeAlD
Drospirenone—Nervous system disorder—Thiotepa—sarcoma	0.00199	0.0119	CcSEcCtD
Drospirenone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	0.00199	0.0103	CbGpPWpGaD
Drospirenone—Skin disorder—Thiotepa—sarcoma	0.00197	0.0118	CcSEcCtD
Drospirenone—Erythema multiforme—Etoposide—sarcoma	0.00194	0.0116	CcSEcCtD
Drospirenone—Angiopathy—Etoposide—sarcoma	0.00186	0.0112	CcSEcCtD
Drospirenone—AR—Nongenotropic Androgen signaling—SRC—sarcoma	0.00183	0.00946	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.00181	0.00937	CbGpPWpGaD
Drospirenone—Nervous system disorder—Vincristine—sarcoma	0.00177	0.0106	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Thiotepa—sarcoma	0.00175	0.0105	CcSEcCtD
Drospirenone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—sarcoma	0.00174	0.00899	CbGpPWpGaD
Drospirenone—Skin disorder—Mitoxantrone—sarcoma	0.0017	0.0102	CcSEcCtD
Drospirenone—Cerebrovascular accident—Epirubicin—sarcoma	0.0017	0.0102	CcSEcCtD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.00169	0.00874	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—FOXO1—sarcoma	0.00168	0.00869	CbGpPWpGaD
Drospirenone—Migraine—Epirubicin—sarcoma	0.00164	0.00982	CcSEcCtD
Drospirenone—Affect lability—Epirubicin—sarcoma	0.00164	0.00982	CcSEcCtD
Drospirenone—PTGS2—Selenium Micronutrient Network—HBA1—sarcoma	0.00161	0.00832	CbGpPWpGaD
Drospirenone—Mood swings—Epirubicin—sarcoma	0.00158	0.00945	CcSEcCtD
Drospirenone—Cerebrovascular accident—Doxorubicin—sarcoma	0.00157	0.00942	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Vincristine—sarcoma	0.00155	0.00932	CcSEcCtD
Drospirenone—AR—FOXA1 transcription factor network—JUN—sarcoma	0.00154	0.00797	CbGpPWpGaD
Drospirenone—AR—Regulation of Androgen receptor activity—MDM2—sarcoma	0.00153	0.0079	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—FUS—sarcoma	0.00152	0.00784	CbGpPWpGaD
Drospirenone—Affect lability—Doxorubicin—sarcoma	0.00152	0.00909	CcSEcCtD
Drospirenone—Migraine—Doxorubicin—sarcoma	0.00152	0.00909	CcSEcCtD
Drospirenone—PTGS2—S1P1 pathway—VEGFA—sarcoma	0.00151	0.00783	CbGpPWpGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00151	0.00906	CcSEcCtD
Drospirenone—Breast disorder—Epirubicin—sarcoma	0.0015	0.00902	CcSEcCtD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	0.0015	0.00776	CbGpPWpGaD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	0.0015	0.00775	CbGpPWpGaD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.00148	0.00765	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.00147	0.00762	CbGpPWpGaD
Drospirenone—Mood swings—Doxorubicin—sarcoma	0.00146	0.00875	CcSEcCtD
Drospirenone—PGR—Signaling by ERBB4—FOXO1—sarcoma	0.00144	0.00743	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—PDGFRB—sarcoma	0.00143	0.00742	CbGpPWpGaD
Drospirenone—Skin disorder—Etoposide—sarcoma	0.00142	0.0085	CcSEcCtD
Drospirenone—PGR—Signaling by ERBB4—PDGFRA—sarcoma	0.00141	0.00731	CbGpPWpGaD
Drospirenone—Breast disorder—Doxorubicin—sarcoma	0.00139	0.00834	CcSEcCtD
Drospirenone—AR—Regulation of Androgen receptor activity—JUN—sarcoma	0.00133	0.00686	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	0.00131	0.0068	CbGpPWpGaD
Drospirenone—AR—Nongenotropic Androgen signaling—HRAS—sarcoma	0.00129	0.00665	CbGpPWpGaD
Drospirenone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—sarcoma	0.00127	0.00657	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Etoposide—sarcoma	0.00126	0.00755	CcSEcCtD
Drospirenone—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—sarcoma	0.00124	0.00639	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—sarcoma	0.00124	0.00639	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—CREB1—sarcoma	0.00122	0.0063	CbGpPWpGaD
Drospirenone—Nausea—Thiotepa—sarcoma	0.00121	0.00723	CcSEcCtD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	0.0012	0.00623	CbGpPWpGaD
Drospirenone—Nausea—Dactinomycin—sarcoma	0.0012	0.00718	CcSEcCtD
Drospirenone—AR—Regulation of Androgen receptor activity—SRC—sarcoma	0.00119	0.00616	CbGpPWpGaD
Drospirenone—AR—Coregulation of Androgen receptor activity—CCND1—sarcoma	0.00119	0.00615	CbGpPWpGaD
Drospirenone—AR—Coregulation of Androgen receptor activity—CTNNB1—sarcoma	0.00118	0.00609	CbGpPWpGaD
Drospirenone—Haemoglobin—Epirubicin—sarcoma	0.00116	0.00694	CcSEcCtD
Drospirenone—Haemorrhage—Epirubicin—sarcoma	0.00115	0.0069	CcSEcCtD
Drospirenone—AR—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.0011	0.00569	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—KIT—sarcoma	0.00109	0.00566	CbGpPWpGaD
Drospirenone—Erythema multiforme—Epirubicin—sarcoma	0.00109	0.00653	CcSEcCtD
Drospirenone—Haemoglobin—Doxorubicin—sarcoma	0.00107	0.00642	CcSEcCtD
Drospirenone—Nausea—Vincristine—sarcoma	0.00107	0.00641	CcSEcCtD
Drospirenone—Haemorrhage—Doxorubicin—sarcoma	0.00106	0.00639	CcSEcCtD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.00106	0.0055	CbGpPWpGaD
Drospirenone—Angiopathy—Epirubicin—sarcoma	0.00104	0.00626	CcSEcCtD
Drospirenone—PGR—Signaling by ERBB4—CREB1—sarcoma	0.00104	0.00539	CbGpPWpGaD
Drospirenone—Nausea—Mitoxantrone—sarcoma	0.00104	0.00625	CcSEcCtD
Drospirenone—Mental disorder—Epirubicin—sarcoma	0.00101	0.00605	CcSEcCtD
Drospirenone—AR—Androgen receptor signaling pathway—MDM2—sarcoma	0.00101	0.00522	CbGpPWpGaD
Drospirenone—Erythema multiforme—Doxorubicin—sarcoma	0.00101	0.00604	CcSEcCtD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000971	0.00502	CbGpPWpGaD
Drospirenone—Angiopathy—Doxorubicin—sarcoma	0.000966	0.00579	CcSEcCtD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	0.000956	0.00495	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	0.000954	0.00494	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	0.000947	0.0049	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	0.000945	0.00489	CbGpPWpGaD
Drospirenone—Mental disorder—Doxorubicin—sarcoma	0.000933	0.0056	CcSEcCtD
Drospirenone—PGR—Gene Expression—FUS—sarcoma	0.000923	0.00478	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000896	0.00464	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—CCND1—sarcoma	0.000878	0.00454	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—JUN—sarcoma	0.000876	0.00453	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—CTNNB1—sarcoma	0.00087	0.0045	CbGpPWpGaD
Drospirenone—Nausea—Etoposide—sarcoma	0.000866	0.0052	CcSEcCtD
Drospirenone—PGR—Signaling by ERBB4—MDM2—sarcoma	0.000862	0.00446	CbGpPWpGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000847	0.00508	CcSEcCtD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.000821	0.00425	CbGpPWpGaD
Drospirenone—Nervous system disorder—Epirubicin—sarcoma	0.000802	0.00481	CcSEcCtD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.000799	0.00413	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000798	0.00413	CbGpPWpGaD
Drospirenone—Skin disorder—Epirubicin—sarcoma	0.000794	0.00476	CcSEcCtD
Drospirenone—AR—Androgen receptor signaling pathway—SRC—sarcoma	0.000786	0.00407	CbGpPWpGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000784	0.0047	CcSEcCtD
Drospirenone—AR—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000778	0.00402	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—KIT—sarcoma	0.000771	0.00399	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	0.000767	0.00397	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000766	0.00396	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	0.000759	0.00393	CbGpPWpGaD
Drospirenone—BCHE—Peptide hormone metabolism—CTNNB1—sarcoma	0.000754	0.0039	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000746	0.00386	CbGpPWpGaD
Drospirenone—Nervous system disorder—Doxorubicin—sarcoma	0.000742	0.00445	CcSEcCtD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000737	0.00381	CbGpPWpGaD
Drospirenone—Skin disorder—Doxorubicin—sarcoma	0.000735	0.00441	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Epirubicin—sarcoma	0.000706	0.00423	CcSEcCtD
Drospirenone—AR—Gene Expression—FUS—sarcoma	0.000703	0.00364	CbGpPWpGaD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.000702	0.00363	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—EGFR—sarcoma	0.000689	0.00356	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000687	0.00355	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000672	0.00347	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000661	0.00342	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.00066	0.00342	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000653	0.00392	CcSEcCtD
Drospirenone—PGR—Signaling by ERBB4—NRAS—sarcoma	0.000647	0.00335	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000634	0.00328	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—EGFR—sarcoma	0.000589	0.00305	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.000575	0.00298	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—JUN—sarcoma	0.000574	0.00297	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.00057	0.00295	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—JUN—sarcoma	0.000559	0.00289	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—KRAS—sarcoma	0.000557	0.00288	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000555	0.00287	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000547	0.00283	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000539	0.00279	CbGpPWpGaD
Drospirenone—BCHE—Transmission across Chemical Synapses—CREB1—sarcoma	0.000533	0.00276	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—CCND1—sarcoma	0.000529	0.00274	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000515	0.00267	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.000502	0.00259	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.000489	0.00253	CbGpPWpGaD
Drospirenone—Nausea—Epirubicin—sarcoma	0.000486	0.00291	CcSEcCtD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000477	0.00247	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000476	0.00246	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—HRAS—sarcoma	0.000473	0.00245	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000472	0.00244	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000461	0.00239	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—NRAS—sarcoma	0.000455	0.00236	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000451	0.00234	CbGpPWpGaD
Drospirenone—Nausea—Doxorubicin—sarcoma	0.000449	0.0027	CcSEcCtD
Drospirenone—BCHE—Transmission across Chemical Synapses—MDM2—sarcoma	0.000441	0.00228	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000427	0.00221	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.000426	0.00221	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—MYC—sarcoma	0.000424	0.00219	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000416	0.00215	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—IL2—sarcoma	0.000413	0.00214	CbGpPWpGaD
Drospirenone—NR3C2—Generic Transcription Pathway—MYC—sarcoma	0.000409	0.00212	CbGpPWpGaD
Drospirenone—BCHE—Neuronal System—CREB1—sarcoma	0.000408	0.00211	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—CCND1—sarcoma	0.000403	0.00208	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TLE1—sarcoma	0.000396	0.00205	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—KRAS—sarcoma	0.000392	0.00203	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000382	0.00198	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.00038	0.00197	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000379	0.00196	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000374	0.00193	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000353	0.00183	CbGpPWpGaD
Drospirenone—BCHE—Neuronal System—MDM2—sarcoma	0.000338	0.00175	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—VEGFC—sarcoma	0.000334	0.00173	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	0.000333	0.00172	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—MYC—sarcoma	0.000323	0.00167	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—EGFR—sarcoma	0.000316	0.00164	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000315	0.00163	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000314	0.00162	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000274	0.00142	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000273	0.00142	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000271	0.0014	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—FLT1—sarcoma	0.000267	0.00138	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—TP53—sarcoma	0.000265	0.00137	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PLCG1—sarcoma	0.000262	0.00136	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CXCR4—sarcoma	0.000252	0.0013	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—MYC—sarcoma	0.000249	0.00129	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ATF1—sarcoma	0.000249	0.00129	CbGpPWpGaD
Drospirenone—PTGS2—Disease—TLE1—sarcoma	0.000248	0.00128	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000245	0.00127	CbGpPWpGaD
Drospirenone—BCHE—Transmission across Chemical Synapses—HRAS—sarcoma	0.000242	0.00125	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000239	0.00124	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ENO2—sarcoma	0.000235	0.00122	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—HBA1—sarcoma	0.000234	0.00121	CbGpPWpGaD
Drospirenone—PTGS2—Disease—NPM1—sarcoma	0.000223	0.00116	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.00022	0.00114	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000215	0.00111	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000203	0.00105	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PLCG1—sarcoma	0.0002	0.00103	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—MYC—sarcoma	0.000197	0.00102	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IGF1R—sarcoma	0.000196	0.00101	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ENO2—sarcoma	0.000193	0.001	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—MYC—sarcoma	0.00019	0.000983	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—FOXO1—sarcoma	0.000186	0.000963	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PDGFRB—sarcoma	0.000186	0.000961	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—MMP2—sarcoma	0.000186	0.00096	CbGpPWpGaD
Drospirenone—BCHE—Neuronal System—HRAS—sarcoma	0.000185	0.000958	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PDGFRA—sarcoma	0.000183	0.000946	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000181	0.000934	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PLCG1—sarcoma	0.000164	0.000849	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ENO2—sarcoma	0.000162	0.000838	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—HBA1—sarcoma	0.000161	0.000833	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CXCR4—sarcoma	0.000158	0.000816	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—KDR—sarcoma	0.000154	0.000797	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—CTNNB1—sarcoma	0.000142	0.000736	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—KIT—sarcoma	0.000142	0.000734	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PLCG1—sarcoma	0.000137	0.000711	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CREB1—sarcoma	0.000135	0.000698	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—MYC—sarcoma	0.00012	0.000621	CbGpPWpGaD
Drospirenone—PTGS2—Disease—FOXO1—sarcoma	0.000116	0.000602	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PDGFRB—sarcoma	0.000116	0.000601	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PDGFRA—sarcoma	0.000114	0.000592	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MDM2—sarcoma	0.000112	0.000578	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IL2—sarcoma	9.98e-05	0.000516	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CCND1—sarcoma	9.73e-05	0.000503	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—JUN—sarcoma	9.71e-05	0.000502	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CTNNB1—sarcoma	9.63e-05	0.000498	CbGpPWpGaD
Drospirenone—AR—Gene Expression—MYC—sarcoma	9.14e-05	0.000473	CbGpPWpGaD
Drospirenone—PTGS2—Disease—KIT—sarcoma	8.87e-05	0.000459	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—SRC—sarcoma	8.71e-05	0.000451	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—VEGFA—sarcoma	8.48e-05	0.000439	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CREB1—sarcoma	8.44e-05	0.000437	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NRAS—sarcoma	8.38e-05	0.000433	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MYC—sarcoma	7.8e-05	0.000404	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—EGFR—sarcoma	7.63e-05	0.000395	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—KRAS—sarcoma	7.21e-05	0.000373	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MDM2—sarcoma	6.99e-05	0.000362	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TP53—sarcoma	6.41e-05	0.000332	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—HRAS—sarcoma	6.13e-05	0.000317	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CTNNB1—sarcoma	6.03e-05	0.000312	CbGpPWpGaD
Drospirenone—PTGS2—Disease—SRC—sarcoma	5.45e-05	0.000282	CbGpPWpGaD
Drospirenone—PTGS2—Disease—NRAS—sarcoma	5.24e-05	0.000271	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MYC—sarcoma	4.88e-05	0.000253	CbGpPWpGaD
Drospirenone—PTGS2—Disease—EGFR—sarcoma	4.77e-05	0.000247	CbGpPWpGaD
Drospirenone—PTGS2—Disease—KRAS—sarcoma	4.51e-05	0.000233	CbGpPWpGaD
Drospirenone—PTGS2—Disease—HRAS—sarcoma	3.83e-05	0.000198	CbGpPWpGaD
